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Aim of the study is to determine the possible roles of p53, cyclin D1, B-catenin and 
Ki-67 in the increase in risk of fractures in patients with giant cell tumor of bone.
The study included a total of 164 patients with giant cell tumor of bone (GCTB), 
21 (12.8%) with and 143 (87.2%) without fracture. The samples were analyzed 
immunohistochemically for expression of Ki-67, p53, cyclin D1 and b-catenin. 
According to the immunohistochemical expression of p53 and Ki-67 in mononu-
clear stromal cells, as well as of cyclin D1 in multinuclear giant cells, there was no 
significant association with immunopositivity and risk of fractures. However, our 
research revealed that patients with cytoplasmic expression of b-catenin in stromal 
cells had three times more frequent occurrence of pathological fractures, which 
was highly statistically significant (χ2 = 7.065; p = 0.008). Moreover, a highly 
statistically significant correlation between the nuclear expression of b-catenin in 
giant cells and the incidence of pathological fractures was also found (χ2 = 8.824; 
p = 0.003).
The study showed that b-catenin expression highly correlates with the incidence of 
pathological fractures in patients with GCTB. Taking into account that b-catenin 
is closely linked to activation of the Wnt signaling pathway in GCTB pathogene-
sis, one could postulate that activation of the Wnt pathway is one of the contribut-
ing factors to locally destructive behavior of this tumor, as well as to the incidence 
of pathological fractures.
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Introduction
Giant cell tumor of bone (GCTB) is a primary 
bone tumor composed of two types of cells: mono-
nuclear and osteoclast-like giant multinuclear cells 
[1, 2]. It usually involves the end of a long bone in 
middle-aged patients. GCTB most commonly oc-
curs in patients 20-40 years of age, and can be found 
in many sites of the body; however, a half of GCTBs 
occur around the knee [3, 4]. Taking into consider-
ation its unclear biological behavior, high recurrence 
rate and possible pulmonary metastasizing, GCTB 
is one of the most controversial and widely discussed 
bone tumors. Pathological fractures occur at first 
presentation in 9.0% to 30.0% of all patients with 
giant cell tumor of bone. The importance of un-
derstanding the incidence of pathological fractures 
in GCTB is evidenced by the fact that its presence 
determines the therapeutic approach, primarily the 
type and extent of surgical intervention [5, 6, 7]. 
Our research involved determining the possible 
role of p53, cyclin D1, B-catenin and Ki-67 in the 
346
Jelena Sopta, nenad luJic, RelJa Kovacevic, et al.
increase in risk of fractures in patients with giant cell 
tumor of bone.
Material and methods 
The analysis included a total of 164 GCTB sam-
ples diagnosed at the Reference Center for Bone and 
Joint Tumors within the Institute for Pathology of 
the Belgrade Faculty of Medicine. All samples belong 
to patients registered in the Bone Tumor Registry 
and treated at the Institute for Orthopedic Surgery 
“Banjica”. 
Pathological fractures were confirmed on the basis 
of relevant radiological and surgical data.
Immunohistochemistry
Serial sections, 5 µm thick, were cut and immuno-
histochemical techniques were carried out using the 
avidin-biotin-peroxidase complex method with an 
LSAB2 kit (Dako, Glostrup, Denmark). The primary 
antibodies used in this study were: p53 (M3629Clone 
318-6-11, dilution 1 : 25; Dako), b-catenin (M3539 
Clone b-catenin1, dilution 1 : 200; Dako), Ki-67 
(M7240 Clone MIB-1, dilution 1 : 100; Dako), and 
cyclin D1 (EPR2241, ab134175, dilution 1 : 200; 
Abcam).
Tumor cells with nuclear staining were considered 
positive in immunohistochemistry for p53, cyclin D1 
and Ki-67. Giant cells with nuclear and stromal cells 
with cytoplasmic staining were considered positive 
in immunohistochemistry for b-catenin. The la-
beled-cell count of all antibodies was determined in 
ten high-power fields at 200× magnification, by two 
blinded independent observer-pathologists. The p53 
expression was evaluated qualitatively in mononucle-
ar tumor cells. For cyclin D1 and b-catenin we ob-
served qualitative positivity separated in giant cells to 
less than 15 nuclei (GC < 15) and cells to 15 or more 
than 15 nuclei (GC ≥ 15). The percentage of positive 
cells for Ki-67 was recorded semi-quantitatively and 
used to obtain a score on a scale of 0-3 as follows: 
score 0 if no positive cells; score 1 if ≤ 5% cells were 
positive; score 2 if 6-19% of cells were positive; score 
3 if ≥ 20% positive cells. In statistics, we used uni- 
and multivariate analyses, and a p-value of less than 
0.05 was accepted as statistically significant.
Results
Demographic characteristics
Out of 164 patients with primary GCTB, 76 were 
men and 88 were women, making the gender ratio 
of 19 : 22. The mean age of first diagnosis was 30.8 
±13.2 years. Duration of symptoms varied from 
1 day (in patients with sudden pathological fractures) 
to 12.6 months (Table I).
Symptoms and localization
The main symptoms were pain and swelling. 
The most frequent localization was the knee region 
– 63.4% (distal femur 42.7% and proximal tibia 
20.7%) (Table I).
Fractures
Our study included 21 patients with pathological 
fractures and typical microscopic tumor presentation 
(Fig. 1A, 2). They represent 12.8% of all patients 
(Table I).
Immunohistochemistry
According to the immunohistochemical expres-
sion of p53 and Ki-67 in mononuclear stromal cells, 
as well as of cyclin D1 in multinuclear giant cells, 
there was no significant association with immunopos-
itivity or risk of fractures (Tables II-IV).
Table I. Basic demographic and clinical characteristics of 
patients
parameter n %
Gender male 76 46.3
female 88 53.7
Age (years) 30.8 ±13.2; 28 (5-64)
Duration  
of symptoms 
(months)
6.2 ±6.3; 4 (1-38)
Pain no 20 12.4
yes 141 87.6
Swelling no 28 17.4
yes 133 82.6
Localization femur 70 42.7
tibia 34 20.7
humerus 12 7.3
scapula 2 1.2
radius 17 10.4
ulna 9 5.5
pelvis 3 1.8
spine 6 3.7
foot 2 1.2
hand 3 1.8
fibula 6 3.7
Pathological 
fracture
no 143 87.2
yes 21 12.8
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Our sample confirmed a twice higher frequency of 
pathological fractures in patients with p53 expressed 
in stromal cells, but statistical analysis showed no sig-
nificance of this difference (χ2 = 2.705; p = 0.100) 
(Table II).
Distributions of patients with pathological frac-
tures were extremely similar, almost identical in each 
of the categories of Ki-67 positivity (χ2 = 0.026; p = 
0.872) (Table III).
Cyclin D1 expression in giant cells with less than 
15 nuclei was most commonly associated with patho-
logical fractures (in 16.5% of patients). Patients with 
cyclin D1 positivity in giant cells with more than 15 
Fig. 1. A) Microscopic appearance of GCTB composed of 
two types of cells: mononuclear cells and osteoclast-like gi-
ant multinuclear cells (HE, original magnification 200×), 
B) b-catenin cytoplasmic expression in mononuclear tumor 
cells (b-catenin, original magnification 400×), C) b-cat-
enin nuclear expression in giant cells (b-catenin, original 
magnification 400×)
A B
C
Table II. Association of pathological fractures with p53 
expression
pathOlOgical 
fracture
tOtal
nO yeS
p53  
in stromal 
cells
no N 61 5 66
% 92.4 7.6 100.0
yes N 82 16 98
% 83.7 16.3 100.0
Total N 143 21 164
% 87.2 12.8 100.0
χ2 = 2.705; p = 0.100
Table III. Association of pathological fractures with 
Ki-67 expression 
pathOlOgical 
fracture
tOtal
nO yeS
Ki-67 0 N 28 4 32
% 87.5 12.5 100.0
≤ 5% N 93 14 107
% 86.9 13.1 100.0
6-19% N 12 2 14
% 85.7 14.3 100.0
≥ 20% N 10 1 11
% 90.9 9.1 100.0
Total N 143 21 164
% 87.2 12.8 100.0
χ2 = 0.026; p = 0.872
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nuclei had no pathological fractures. Nevertheless, 
the difference was not statistically significant (χ2 = 
0.007; p = 0.933) (Table IV).
By means of correlating b-catenin expression with 
the incidence of pathological fractures, we found 
a highly statistically significant correlation between 
these two features in our sample (Table V).
Our research revealed that patients with cyto-
plasmic expression of beta-catenin in stromal cells 
(Fig. 1B) had three times more frequent incidence of 
pathological fractures, which was highly statistically 
significant (χ2 = 7.065; p = 0.008).
Moreover, a highly statistically significant correla-
tion between the nuclear expression of b-catenin in 
giant cells (Fig. 1C) and the incidence of pathological 
fractures was also found (χ2 = 8.824; p = 0.003).
Table IV. Cyclin D1 as compared to pathological fractures
pathOlOgical 
fracture
tOtal
nO yeS
Cyclin D1  
in giant  
cells
0 N 37 3 40
% 92.5 7.5 100.0
< 15  
nuclei
N 91 18 109
% 83.5 16.5 100.0
15+  
nuclei
N 15 0 15
% 100.0 0.0 100.0
Total N 143 21 164
% 87.2 12.8 100.0
χ2 = 0.007; p = 0.933
Table V. Association of b-catenin expression in stromal and giant cells with the occurrence of pathological fractures
pathOlOgical fractureS
yeS nO tOtal
b-catenin  
in stromal 
cells
yes N 85 6 91
% 93.4 6.6 100.0
no N 58 15 73
% 79.5 20.5 100.0
0 N 92 8 100
% 92.0 8.0 100.0
b-catenin  
in giant  
cells 
< 15 nuclei N 43 8 51
% 84.3 15.7 100.0
15+ nuclei N 8 5 13
% 61.5 38.5 100.0
Total N 143 21 164
% 87.2 12.8 100.0
Discussion
GCT is a locally aggressive and purely osteolyt-
ic skeletal lesion [1, 3, 4, 7]. Pathological fractures 
can be caused by tumor invasion and associated with 
stress. They represent a relatively frequent complica-
tion found in 9-30% of patients with GCTB [4, 8]. 
The prevalence of pathological fractures in this study 
was 12.8%, which was in compliance with the find-
ings of other authors.
Causes of pathological fractures are multifactorial 
and still insufficiently known. An additional possible 
parameter leading to the incidence of pathological 
fractures is the activation of the Wnt pathway of car-
cinogenesis described in GCTB [9, 10, 11, 12]. Indi-
vidual genes included in the Wnt pathway influence 
the destructivity of GCTB and promote cell growth. 
It is widely known that b-catenin has an important 
role in the Wnt signaling pathway, as well as in the 
incidence of numerous primary mesenchymal tumors 
of bone and soft tissue [11, 12, 13, 14].
Our research reaffirmed that b-catenin expression 
in the cytoplasm of mononuclear cells, as well as in 
giant cell nuclei, was associated with a high risk of 
fracture incidence with GCTB. Tumors with stromal, 
mononuclear cells displaying cytoplasmic positivity 
to b-catenin were three times more frequently mani-
fested, both clinically and radiologically, by the inci-
dence of pathological fractures. Nuclear expression of 
b-catenin in giant multinuclear, osteoclast-like cells 
was highly statistically correlated with the incidence 
of fractures. Positivity to b-catenin in GCTB cells in-
dicated activation of the Wnt pathway in GCTB, as 
well as the possible importance of this signaling path-
349
β-catenin expression in giant cell tumors of bone
Fig. 2. Native radiography – GCTB in proximal femur 
with pathologic fracture
way, both for the pathogenesis and for locally aggres-
sive behavior of this primary bone tumor. 
Bearing in mind that Shuxin et al. [15] confirmed 
that the JUN gene, which is a part of the Wnt path-
way activated in GCTB, was in charge of promoting 
stromal cell growth and increasing the destructivi-
ty of this tumor, this could be used for explaining 
the association with pathological fractures. It is also 
known that the JUN gene plays a very important role 
in the canonical Wnt signaling pathway, primarily 
by interacting with b-catenin – TCFs transcription-
al complex. Therefore, b-catenin expression indicates 
increased transcription in GCTB, as well as possible 
hyperactivation of the JUN gene [14, 15, 16].
In addition, this gene, which is closely linked 
to b-catenin, correlates with positive regulation 
of matrix metalloproteinases, which have a great 
significance for dyscoherence of tumor cells, and 
therefore locally aggressive biological behavior. The 
following matrix metalloproteinases are highly pos-
itive in GCTB: MMP-2, MMP-13 and MMP-9. The 
role of MMP-13 is to optimize bone resorption by 
giant osteoclast-like cells, whereas its high expres-
sivity in GCTB could be responsible for the occur-
rence of osteolysis and pathological fractures [15, 
16, 17, 18].
Both the JUN gene and b-catenin could also im-
pact certain physiological processes in extracellular 
matrix, by promoting growth and emphasizing de-
structivity in GCTB.
Conclusions
The importance of understanding the occurrence 
of pathological fractures in GCTB is evident in the 
fact that its presence determines the therapeutic 
approach, primarily the type and extent of surgi-
cal intervention. The study showed that b-catenin 
expression highly correlates with the incidence of 
pathological fractures in GCTB patients. Taking into 
account that b-catenin is closely linked to activation 
of the Wnt signaling pathway in GCTB pathogen-
esis, one could postulate that activation of the Wnt 
pathway is one of the contributing factors for locally 
destructive behavior of this tumor, as well as for the 
incidence of pathological fractures.
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